Description: JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Home Page: www.jwtherapeutics.com
Building B
Shanghai,
China
Phone:
400 820 0033
Officers
| Name | Title |
|---|---|
| Dr. Yiping Li M.D. | Co-founder, Exec. Chairman & CEO |
| Mr. Xin Fu | Sr. VP & CFO |
| Cao Xiaoping Ph.D. | Sr. VP of Tech Operations |
| Dr. Shaun Paul Cordoba Ph.D. | Chief Scientific Officer |
| Mr. Raymond J. Hage Jr. | Sr. VP of Corp. Devel. |
| Dr. Hongxiang Zheng M.D., Ph.D. | Sr. VP |
| Mr. Qiong Wu | Sr. VP & Chief Commercial Officer |
| Mr. Mark J. Gilbert M.D. | Sr. Advisor & Acting Chief Medical Officer |
| Mr. Wenjun Sun | Sr. VP of Bus. Devel. |
| Ms. Ka Man Ng A.C.I.S., A.C.S., ACIS, ACS | Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6903 |
| Price-to-Sales TTM: | 18.4269 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 589 |